Three Treatment Methods via the Hepatic Artery for Hepatocellular Carcinoma - A Retrospective Study

Teng-Chuang Ma, Hai-Bo Shao, Yang Xu, Ke Xu*

Abstract

Background: To evaluate the relative effectiveness of different treatments of hepatocellular carcinoma (HCC) via the hepatic artery. Materials and Methods: The study sample group consisted of 418 patients who were randomly selected from 2008 to 2012 with a first diagnosis of HCC and treated with transcatheter arterial chemoembolization (TACE) or without (TAE) chemotherapy or transcatheter arterial infusion (TAI). We collected data including tumor size preoperative and one month thereafter to compare change in areas across the three groups, along with various laboratory indexes for comparison. Results: The overall average change of areas was 240.8±72.1 mm². In the three groups it was 265.0±58.0 mm² vs. 250.5±51.9 mm² vs. 123.7±26.2 mm². In groups TACE and TAE values were larger than in group TAI (p<0.01), but the difference between the two was not statistically significant (p= 0.191). Additionally, U/L change of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in groups TACE and TAE was greater than in the TAI cases (24.0±13.5 vs. 20.9±12.1 vs. 5.47±8.20 and 25.6±13.5 vs.23.2±12.28 vs.5.48±14.3) on the preoperative day and two days thereafter (p<0.01). Between the two groups there was no significant cariation (p= 0.320 and p= 0.609). However, the AST and ALT recovered to normal levels one month later on therapy with liver protecting drugs. Conclusion: The groups TACE and TAE demonstrated more effective reduction of tumor size than group TAI. While lipiodol caused acute liver function damage, this proved reversible.

Keywords: HCC - effect - intervention treatment - hepatic artery - retrospective

Introduction

Treatment of hepatocellular carcinoma (HCC) via hepatic artery is mainly suitable for the patients who have lost the chance of surgical resection (Lencioni et al., 2012), it also applies to those who have other contraindications of minimally invasive treatment. There are three main methods via the hepatic artery. However, the comparison of relative effectiveness of them for hepatocellular carcinoma (HCC) is scanty. Morse et al reported that the addition of chemotherapy to TAE prolongs progression-free survival (PFS) and time to progression (TTP). Future efforts should focus on adjunctive therapies after the embolization to increase survival (Morse et al., 2012). However, Llovet et al indicated that chemoembolization improves survival of patients with unresectable HCC (Llovet et al., 2003). Morse et al reported that the addition of chemotherapy to TAE prolongs progression-free survival (PFS) and time to progression (TTP). Future efforts should focus on adjunctive therapies after the embolization to increase survival (Morse et al., 2012). However, Llovet et al indicated that chemoembolization improves survival of patients with unresectable HCC (Llovet et al., 2003). A meta-analysis that compared TACE versus TAE in nine trials with 645 participants claimed that there is no firm evidence to support or refute TACE or TAE for patients with unresectable HCC. More adequately powered and bias-protected trials are needed (Oliveri et al., 2011; Farinati et al., 2012; Fornier et al., 2012). Another meta-analysis indicated that there is no survival advantage associated with therapeutic embolization versus supportive care alone in patients with unresectable hepatocellular carcinoma. Existing survival data from randomized controlled trials are of poor quality (Geschwind et al., 2003). At the same time, Bruix et al found that arterial embolization improved 2-year survival versus control and this benefit was significant for TACE but not for TAE (Bruix et al., 2001). Cammà et al demonstrated that both TACE/TAE significantly reduced overall 2-year mortality, but the magnitude of benefit was relatively low (Cammà et al., 2002). Takayama et al reported that HAI-TAE-hyperthermia combination therapy was favorable for the treatment of advanced liver cancer (Izumi et al., 1998; Takayama et al., 1998). But there was no clear report to assess the efficacy of TAI and TACE/TAE in patients with HCC. Ikoma A et al compared three intervention methods in the swine models (Ikoma et al., 2012), it was highly concluded that although the necrosis volume ratio of the liver was tolerable, lipiodol-TACE caused the greatest delay in outflow ratio for each cancer drug and the greatest negative effect to liver in a swine model. From the above, these investigation teams were
conducted in specialized difference centers in selected patients. In our retrospective study we focus on the perspective in change of the tumor sizes and analyzed the preoperative and postoperative changes of various laboratory indexes among three intervention groups.

Materials and Methods

Study Subjects and Endpoint

This study was a retrospective design. All patients first diagnosed with HCC and treated with any intervention therapy via hepatic artery from 2008 to 2012 in the hospital. We had strict inclusion criteria: all the Child-Pugh score C patients were excluded, also including those over the age of 75 and the longest diameter of tumor was more than 10 cm were excluded, as well as the patients with portal vein thrombosis and metastases. A month was selected as the unique endpoint to evaluate the efficacy. The study protocol was approved by the ethic committees of all the participating Institutions.

Variables chosen

All the research parameters were obtained in clinical records, we collected the images of contrast-enhanced CT preoperative and a month after the operation of the patient, the same method was used to evaluate the area of the tumor.

Figure 1. Measurement Method of Change Areas. A: The CT image for hepatocellular carcinoma patients who was first time to be diagnosed of preoperative, we measure its area by calculating the longest diameter of the image. B: That the CT image for a month after the operation of the patient, the same method was used to evaluate the area of the tumor.

Table 1. Baseline Characteristics of the Study Patients by Treatment

| Variable                          | Total (N=418) | TACE (N=247) | TAE (N=111) | TAI (N=60) |
|-----------------------------------|--------------|--------------|-------------|------------|
| Year of diagnosis                 |              |              |             |            |
| 2008                              | 81(19%)      | 42(17%)      | 26(23%)     | 13(22%)    |
| 2009                              | 92(22%)      | 50(20%)      | 19(17%)     | 23(38%)    |
| 2010                              | 105(25%)     | 69(28%)      | 32(29%)     | 4(7%)      |
| 2011                              | 74(18%)      | 46(19%)      | 15(14%)     | 13(22%)    |
| 2012                              | 66(16%)      | 40(16%)      | 19(17%)     | 7(12%)     |
| Male gender                       | 309(74%)     | 189(77%)     | 94(85%)     | 26(43%)    |
| Age yrs, mean(SD)                 | 66(7)        | 62(8)        | 68(7)       | 64(8)      |
| Diagnostic assessment             |              |              |             |            |
| Histology                         | 211(50%)     | 126(51%)     | 52(47%)     | 33(55%)    |
| CT+AFP>400                        | 88(21%)      | 53(21%)      | 25(23%)     | 10(17%)    |
| CT only                           | 119(29%)     | 68(28%)      | 34(30%)     | 17(28%)    |
| Underlying liver disease           |              |              |             |            |
| Liver cirrhosis                   | 411(98%)     | 244(99%)     | 108(97%)    | 59(98%)    |
| Chronic Hepatitis                 | 7(2%)        | 3(2%)        | 3(3%)       | 1(2%)      |
| Etiology                          |              |              |             |            |
| Viral                             | 359(86%)     | 217(88%)     | 92(83%)     | 50(83%)    |
| Nonviral                          | 42(10%)      | 25(10%)      | 14(13%)     | 3(5%)      |
| Missing                           | 17(4%)       | 5(2%)        | 5(5%)       | 7(12%)     |
| Viral etiology                    |              |              |             |            |
| HBV                               | 334(81%)     | 203(82%)     | 84(76%)     | 46(92%)    |
| HCV                               | 25(6%)       | 14(6%)       | 8(7%)       | 4(8%)      |
| Child-pugh score                  |              |              |             |            |
| A                                 | 298(71%)     | 163(66%)     | 98(88%)     | 37(62%)    |
| B                                 | 120(29%)     | 84(34%)      | 13(12%)     | 23(38%)    |
| Numbers of nodules                |              |              |             |            |
| <3                                | 335(80%)     | 203(82%)     | 79(71%)     | 53(88%)    |
| ≥3                                | 83(20%)      | 44(18%)      | 32(29%)     | 7(12%)     |

Data were reported as Absolute Numbers (Percentages), but for Age (BUN) the day before operation and the second day of postoperative.

Statistical analysis

First we calculated the comparison of difference among three groups by using the data that we collected. After then we conducted every two sets of comparisons in that. All the data including preoperative and postoperative changes of various laboratory indexes were compared with Kruskal-Wallis test. Results were expressed as mean ± standard (S.D). All analyses were conducted via Statistical Package for Social Sciences, version 19.0 (SPSS Inc., Chicago, IL, USA). The difference is considered statistically significant by this study if a p value is less than 0.01.

Results

Over 609 HCC patients were randomly selected from 2008 to 2012, 105 of that was not the first time for intervention treatment were excluded. About 59 patients who had surgical resection or radio frequency ablation (RFA) and 27 patients that did not find preoperative contrast-enhanced CT images were also excluded. Baseline characteristics of 418 patients were reported in Table 1. There was no significant difference among three groups. It was clearly found that TACE was the common method for HCC patients (59%), TAE mainly suitable
Discussion

In our retrospective study, we found that the difference in the reduction of tumor sizes among three groups. Although powered randomized trials need to verify this conclusion, but our study provides the directions and possibilities. Someone concerned that HCC was very chemoresistant, thus embolization may be more important than chemotherapy (Marelli et al., 2007; Pleguezuelo et al., 2008). Whether use the chemotherapy drugs for unresectable patients with HCC in hepatic artery embolization is becoming a focus of discussion. Further studies should investigate if the new available embolization agents or drug eluting beads may improve the effect on tumor necrosis (Miraglia et al., 2007). Simultaneously, whether some of the different chemotherapy drugs combined can obtain definitely results need more randomized trials.

The most accurate support for our observation was that ALT respectively (Figure 3). It was clear that lipiodol embolization of hepatic artery resulted in an acute damage of liver function. Then by observing other laboratory parameters of the changes between preoperative and postoperative, there was no statistically difference among three groups (Figure 4).

Discussion

In our retrospective study, we found that the difference in the reduction of tumor sizes among three groups. Although powered randomized trials need to verify this conclusion, but our study provides the directions and possibilities. Someone concerned that HCC was very chemoresistant, thus embolization may be more important than chemotherapy (Marelli et al., 2007; Pleguezuelo et al., 2008). Whether use the chemotherapy drugs for unresectable patients with HCC in hepatic artery embolization is becoming a focus of discussion. Further studies should investigate if the new available embolization agents or drug eluting beads may improve the effect on tumor necrosis (Miraglia et al., 2007). Simultaneously, whether some of the different chemotherapy drugs combined can obtain definitely results need more randomized trials.

The most accurate support for our observation was that ALT respectively (Figure 3). It was clear that lipiodol embolization of hepatic artery resulted in an acute damage of liver function. Then by observing other laboratory parameters of the changes between preoperative and postoperative, there was no statistically difference among three groups (Figure 4).

Discussion

In our retrospective study, we found that the difference in the reduction of tumor sizes among three groups. Although powered randomized trials need to verify this conclusion, but our study provides the directions and possibilities. Someone concerned that HCC was very chemoresistant, thus embolization may be more important than chemotherapy (Marelli et al., 2007; Pleguezuelo et al., 2008). Whether use the chemotherapy drugs for unresectable patients with HCC in hepatic artery embolization is becoming a focus of discussion. Further studies should investigate if the new available embolization agents or drug eluting beads may improve the effect on tumor necrosis (Miraglia et al., 2007). Simultaneously, whether some of the different chemotherapy drugs combined can obtain definitely results need more randomized trials.

The most accurate support for our observation was that ALT respectively (Figure 3). It was clear that lipiodol embolization of hepatic artery resulted in an acute damage of liver function. Then by observing other laboratory parameters of the changes between preoperative and postoperative, there was no statistically difference among three groups (Figure 4).
we refer to each patient contrast-enhanced CT images of preoperative and postoperative. Careful analysis of images and the calculation of area difference were performed by us, then we inspected the data and carried on the statistical analysis. For the laboratory indexes observation, we compared parameters the day of preoperative and the two days after the operation. it is concluded that lipiodol caused acute liver function damage. However, we also collected the liver function parameters of three groups patients a month later after the operation. The liver function of three groups recovered to normal level. There was no statistically significant among three groups to compare with the data of preoperative in liver function series by using mann-whitney u test (Figure 5). This month follow-up period clearly demonstrated that three groups of patients treated with the same protection liver function drugs. It is described that although lipiodol can cause acute liver function damage, it is reversible by using the protection drugs.

Our study also has some important limitations. First, we randomly selected patients with HCC those were carried on the operation by different persons. The level and habits of different operators may affect the results of embolization and thereby influence the results of the study. Second, we evaluated the change of tumor areas by measuring the longest diameter of contrast-enhanced CT. However, this method can be influenced by many factors that confused the results of the study. Third, patients of three groups in the postoperative had different nutritional status and recovery rata, so the larger deviations may appear in liver function indexes. Fouth, we just analyzed some of the more important parameters and not for others, it produced some bias that we unexpected.

In conclusion, this retrospective study focused on 418 patients with HCC who accepted TACE, TAE and TAI different intervention operation. The groups TACE and TAE gained a greater impact in tumor size changes than group TAI, but there was no difference between the two ones. We found that lipiodol caused acute liver function damage. However, this kind of damage can be restored by the treatment of liver protection drugs.

Acknowledgements

The study was partially supported by the National High Technology Research and Development Program of China (863 Program) No. 2012AA022701.

References

Bruix J, Sherman M, Llovet JM, et al (2001). Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. *Hepatol J*, 35, 421-30.
Cammà C, Schepis F, Orlando A, et al (2002). Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. *Radiology J*, 224, 47-54.
Farinati F, Giacomin A, Vanin V, et al (2012). TACE treatment in hepatocellular carcinoma: what should we do now. *Hepatol J*, 57, 221-2.
Forner A, Llovet JM, Bruix J (2012). Chemoembolization for intermediate HCC: is there proof of survival benefit. *Hepatol J*, 56, 984-6.
Geschwind JF, Ramsey DE, Choti MA, et al (1988). Chemoembolization of hepatocellular carcinoma: results of a metaanalysis. *Clin Oncol AM J*, 26, 344-9.
Ikoma A, Kawai N, Sato M, et al (2012). Comparison of blood dynamics of anticancer drugs (cisplatin, mitomycin C, epirubicin) in treatment groups of hepatic arterial infusion, hepatic arterial infusion with lipiodol and transcatheter arterial chemoembolization with lipiodol plus gelatin sponge particles in a swine model. *Hepatol Res J*, 42, 1227-35.
Izumi R, Urade M, Kimura H, et al (1988). Combined hepatic arterial infusion chemotherapy with transcatheter arterial embolization and hyperthermia in primary liver cancer. *Gan To Kagaku Ryoho*, 15, 2465-9.
Lencioni R (2012). Chemoembolization for hepatocellular carcinoma. *Semin Oncol J*, 39, 503-9.
Llovet JM, Bruix J (2003). Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. *Hepatology J*, 37, 429-42.
Marelli L, Stigliano R, Triantos C, et al (2007). Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. *Cardiowase Intervent Radiol J*, 30, 6-25.
Miraglia R, Pietrosi G, Maruzzelli L, et al (2007). Efficacy of transcatheter embolization (TAE/TACE) for the treatment of single hepatocellular carcinoma. *World J Gastroenterol J*, 13, 2952-5.
Morse MA, Hanks BA, Suhocki P, et al (2012). Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma. *Clin Colorectal Cancer J*, 11, 185-90.
Oliveri RS, Wetterslev J, Gluud C (2011). Transarterial (chemo) embolisation for unresectable hepatocellular carcinoma. *Cochrane Database Syst Rev*, 16, CD004787.
Pleguezuelo M, Marelli L, Misseri M, et al (2008). TACE versus TAE as therapy for hepatocellular carcinoma. *Expert Rev Anticancer Ther*, 8, 1623-41.
Takayama W, Asano T, Kobayashi S, et al (1998). Hepatic arterial infusion chemotherapy (HAI) for advanced hepatocellular carcinoma inefficacious with transcatheter arterial embolization (TAE). *Gan To Kagaku Ryoho*, 25, 867-71.